OraSure’s Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack
28 7월 2022 - 8:05PM
OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in
point-of-care and home diagnostic testing and sample collection
technologies, announced today its ongoing commitment to fight the
hepatitis C epidemic. July 28 is commemorated around the globe each
year as World Hepatitis Day. Organizations such as the World Health
Organization (WHO) and the U.S. Centers for Disease Control (CDC)
use this day as an opportunity to educate people about hepatitis
infections.
For the second year in a row, OraSure is proud
to collaborate with the Will Rodgers Liver Health Foundation in his
efforts to teach people about liver disease. Founded by NASCAR
driver Will Rodgers, OraSure sponsors the foundation’s Race to End
Hep C initiative, which gives individuals at select NASCAR events
access to free Hepatitis C (HCV) testing, using the OraQuick® HCV
Rapid Antibody Test that provides results in 20 minutes. During
2021’s Race to End Hep C efforts, 2.5 percent of the 351 people who
were tested for HCV at racetracks nationwide had a positive result
and were linked to care.
“Hepatitis C is a public health crisis in this
country with increasing incidence nationwide. The true problems
with combatting this terrible and burdensome disease are both
access to care – given the disparities in our healthcare system –
and awareness, with four in 10 individuals who have hepatitis C
unaware of their infection status,” said Lisa Nibauer, President of
Diagnostics for OraSure Technologies. “Our partnership with the
Will Rodgers Liver Health Foundation highlights the ability of
simple-to-administer, low-cost tests to drive disease awareness and
point people to appropriate care. This is a treatable disease, and
early diagnosis can dramatically improve patient outcomes and lower
costs for our healthcare system.”
HCV is a viral infection that causes
inflammation of the liver and can lead to liver cirrhosis, liver
cancer, and liver failure. According to the CDC, about 2.4 million
adults in the U.S. are living with HCV and about 40 percent do not
know they have it. CDC recommends that everyone ages 18 and older
get tested for HCV at least once in their lifetime.
To find a Race to End Hep C event near you,
visit www.RaceToEndHepC.com.
About HCV and the OraQuick® HCV Rapid
Antibody TestAccording to the CDC, HCV is the most common
chronic blood-borne infection in the United States, with
approximately 2.4 million people infected. It is estimated that one
in 30 Baby Boomers (adults born between 1945 and 1965) have chronic
Hepatitis C and about 40 percent of the people infected with HCV in
the United States are unaware of their infection. The CDC, the U.S.
Preventive Services Task Force (USPSTF), and the American
Association for the Study of Liver Diseases (AASLD) have all issued
guidance that recommends HCV testing for anyone over the age of 18,
including all Baby Boomers.
The OraQuick® HCV Rapid Antibody Test is the
first and only FDA-approved and CLIA-waived point of care test for
detection of HCV infection in at-risk individuals. The simple
platform enables healthcare providers to deliver results in 20
minutes, using venipuncture or fingerstick blood.
About the Will Rodgers Liver Health
FoundationBy uniting the healthcare industry, the Will
Rodgers Liver Health Foundation (WRLHF) seeks to build awareness
and provide education on liver disease, remove any barriers for
treatment of liver diseases for targeted demographics, provide
linkage to care in targeted communities, and eliminate negative
stigma surrounding liver disease. The WRLHF fills a need for a
national, far-reaching campaign, coupled with a true ambassador for
liver health. The foundation focuses on consumable education for
the public, provides on-site and in-the-field testing, and links
patients with proper care. Additionally, the WRLHF stands to change
the public’s negative perception of liver disease and has a goal to
positively change the conversation. For more information on the
Will Rodgers Liver Health Foundation, visit
www.liverhealth.foundation.
About OraSure
TechnologiesOraSure Technologies empowers the global
community to improve health and wellness by providing access to
accurate, essential information. OraSure, together with its
wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis,
provides its customers with end-to-end solutions that encompass
tools, services and diagnostics. The OraSure family of companies is
a leader in the development, manufacture, and distribution of rapid
diagnostic tests, sample collection and stabilization devices, and
molecular services solutions designed to discover and detect
critical medical conditions. OraSure’s portfolio of products is
sold globally to clinical laboratories, hospitals, physician’s
offices, clinics, public health and community-based organizations,
research institutions, government agencies, pharma, commercial
entities and direct to consumers. For more information on OraSure
Technologies, please visit www.orasure.com.
Important InformationThis press
release contains certain forward-looking statements, including with
respect to the Company’s products, product development activities,
regulatory submissions and authorizations and other matters.
Forward-looking statements are not guarantees of future performance
or results. Known and unknown factors that could cause actual
performance or results to be materially different from those
expressed or implied in these statements include, but are not
limited to: risk that the Company's exploration of strategic
alternatives may not result in any definitive transaction or
enhance stockholder value and may create a distraction or
uncertainty that may adversely affect operating results, business
or investor perceptions; the diversion of management’s attention
from the Company's ongoing business and regular business
responsibilities due to the Company's exploration of strategic
alternatives; ability to resolve the Company's ongoing
manufacturing challenges and satisfy customer demand; ability to
market and sell products, whether through our internal, direct
sales force or third parties; impact of significant customer
concentration in the genomics business; failure of distributors or
other customers to meet purchase forecasts, historic purchase
levels or minimum purchase requirements for our products; ability
to manufacture products in accordance with applicable
specifications, performance standards and quality requirements;
ability to obtain, and timing and cost of obtaining, necessary
regulatory approvals for new products or new indications or
applications for existing products; ability to comply with
applicable regulatory requirements; ability to effectively resolve
warning letters, audit observations and other findings or comments
from the U.S. Food and Drug Administration (“FDA”) or other
regulators; the impact of the novel coronavirus (“COVID-19”)
pandemic on the Company's business and ability to successfully
develop new products, validate the expanded use of existing
collector products, receive necessary regulatory approvals and
authorizations and commercialize such products for COVID-19
testing; changes in relationships, including disputes or
disagreements, with strategic partners or other parties and
reliance on strategic partners for the performance of critical
activities under collaborative arrangements; ability to meet
increased demand for the Company’s products; impact of replacing
distributors; inventory levels at distributors and other customers;
ability of the Company to achieve its financial and strategic
objectives and continue to increase its revenues, including the
ability to expand international sales; impact of competitors,
competing products and technology changes; reduction or deferral of
public funding available to customers; competition from new or
better technology or lower cost products; ability to develop,
commercialize and market new products; market acceptance of oral
fluid or urine testing, collection or other products; market
acceptance and uptake of microbiome informatics, microbial genetics
technology and related analytics services; changes in market
acceptance of products based on product performance or other
factors, including changes in testing guidelines, algorithms or
other recommendations by the Centers for Disease Control and
Prevention (“CDC”) or other agencies; ability to fund research and
development and other products and operations; ability to obtain
and maintain new or existing product distribution channels;
reliance on sole supply sources for critical products and
components; availability of related products produced by third
parties or products required for use of our products; impact of
contracting with the U.S. government; impact of negative economic
conditions; ability to maintain sustained profitability; ability to
utilize net operating loss carry forwards or other deferred tax
assets; volatility of the Company’s stock price; uncertainty
relating to patent protection and potential patent infringement
claims; uncertainty and costs of litigation relating to patents and
other intellectual property; availability of licenses to patents or
other technology; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing
of products; ability to sell products internationally, including
the impact of changes in international funding sources and testing
algorithms; adverse movements in foreign currency exchange rates;
loss or impairment of sources of capital; ability to attract and
retain qualified personnel; exposure to product liability and other
types of litigation; changes in international, federal or state
laws and regulations; customer consolidations and inventory
practices; equipment failures and ability to obtain needed raw
materials and components; the impact of terrorist attacks and civil
unrest; and general political, business and economic conditions.
These and other factors that could affect our results are discussed
more fully in our SEC filings, including our registration
statements, Annual Report on Form 10-K for the year ended December
31, 2021, Quarterly Reports on Form 10-Q, and other filings with
the SEC. Although forward-looking statements help to provide
information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. Readers are
cautioned not to place undue reliance on the forward-looking
statements. The forward-looking statements are made as of the date
of this press release and OraSure Technologies undertakes no duty
to update these statements.
Investor
Contact: |
|
Media
Contact: |
Scott Gleason |
|
Amy Koch |
SVP Investor Relations & Corporate Communications |
|
Sr. Mgr. Corporate Communications |
484-425-0588 |
|
484-523-1815 |
sgleason@orasure.com |
|
media@orasure.com |
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024